Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.52 +0.01 (+0.01%)
Streaming Delayed Price Updated: 3:05 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE: BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
From Bristol Myers Squibb
Via Business Wire
3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now. 
Via The Motley Fool
Exposures COVID-19
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
3 Pharma Stocks That Are Too Cheap to Ignore
Many stocks are ridiculously expensive right now -- but not these three. 
Via The Motley Fool
Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis
The European Commission has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) for ulcerative colitis (UC). The approval comes for adult... 
Via Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today
Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday. 
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Bristol Myers Squibb Is a Table-Pounding Buy
Value investors can take advantage of the huge discrepancy between the company's valuation and its fundamentals. 
Via The Motley Fool
Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay
Bristol Myers Squibb & Co (NYSE: BMY) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid... 
Via Benzinga
Exposures Product Safety
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Over the past 3 months, 5 analysts have published their opinion on Bristol-Myers Squibb (NYSE: 
Via Benzinga
2 Dividend Stocks to Buy Right Now
These two drugmakers have a solid track record. 
Via The Motley Fool
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
From Bristol Myers Squibb
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3
Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock... 
Via Benzinga
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
From Bristol Myers Squibb
Via Business Wire
Tuesday Market Overview
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
Bristol Myers Squibb, Janssen Move Closer To Phase 3 For Blood Thinner Candidate
Bristol Myers Squibb & Co (NYSE: BMY) and Johnson & Johnson's (NYSE: JNJ) unit Janssen Pharmaceuticals Inc announced results from the... 
Via Benzinga
Warren Buffett Stocks: Berkshire Hathaway To Reveal Q3 Stock Buys And Sells
Berkshire Hathaway will file its 13-F, detailing changes to its stock holdings. 
Via Investor's Business Daily
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease
Bristol Myers Squibb & Co (NYSE: BMY) has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout. Heart patients... 
Via Benzinga
Bristol-Myers Squibb Q3 Earnings: What Investors Should Know
The stock has underperformed the market over the long term. 
Via The Motley Fool
Better Buy: Bristol Myers Squibb vs. Merck
Which pharma giant is right for you? 
Via The Motley Fool
Exposures COVID-19
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
Why Compugen Surged 14% Higher on Thursday
The company is deepening its partnership with Bristol Myers Squibb. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.